<DOC>
	<DOCNO>NCT00320294</DOCNO>
	<brief_summary>To compare combination irinotecan , leucovorin 5-FU ( ILF ) ILF plus cisplatin ( PILF ) first-line chemotherapy patient measurable metastatic gastric cancer .</brief_summary>
	<brief_title>ILF With/Without Cisplatin Advanced Gastric Cancer</brief_title>
	<detailed_description>Irinotecan , combination 5-FU cisplatin , clearly demonstrate efficacy gastric cancer . A previous randomize study ILF regimen versus IP patient AGC show ILF produce overall response rate 42 % median survival 10.7 month , significantly good result IP regimen [ Pozzo C , et al . Ann Oncol 2004 ] . However , since cisplatin still consider one key drug treatment gastric cancer , combination four drug ( irinotecan , leucovorin , FU cisplatin ) seem promising strategy advance AGC . We desinged randomize phase II study compare combination irinotecan , leucovorin 5-FU ( ILF ) ILF plus cisplatin ( PILF ) first-line chemotherapy patient measurable metastatic gastric cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven gastric adenocarcinoma Advanced , metastatic recurrent ECOG performance status 0 2 No prior chemotherapy Measurable evaluable indicator lesion ( ) Normal marrow , hepatic renal function Provision write informed consent Active infection , bleed severe comorbidities Pregnant breastfed woman Active CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>